Aim To report a case in France where the application of the French regulation on drug imports blocked the use of a French registered drug.
Introduction
In Europe, regulations about drug imports and exports were based on the fear of introducing unsafe drugs from countries where the drug registration process may be weak (Blanc 1997) . This logical and consistent objective may be forgotten by the authorities in charge of applying it. We report a case where the application of the French regulation on drug imports (French Public Health Code-FPHC) prevented the use in France of a French registered drug.
Concerning the regulatory context, since 1965, in Europe (65/65/EC Directive) drugs for human use can only be marketed after obtaining a marketing authorisation (MA) from a health authority; in France, now the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) issues drug MA by national procedure. The role of this agency is also to issue some special authorisations regarding drugs, including import authorisations.
Concerning the clinical context, dextran 40 is a polymer with known inhibitory effects on the complement system and intrinsic coagulation pathway; it is used as a graftpreservation solution in lung transplantation (Perfadex®) (Reichart et al. 2003) . As a drug (Rheomacrodex®), it was authorised as an intravascular fluid volume replacement solution and for prophylaxis of postoperative venous thrombosis.
Case description
One of us (EF), during a stay in Toronto General Hospital (Ontario, Canada) in 2005, observed favourable outcomes for lung transplantation bronchial sutures of an immediate postoperative protocol including 500 ml per day of 10% dextran 40 in 5% dextrose infusion for 7 days.
In October 2005, we intended to include this therapeutic protocol in our standard practice. We identified a drug with dextran 40 (Rheomacrodex®) with a valid MA and labelled as an intravascular fluid volume replacement solution, but the drug had not been actively marketed since March 2000. A search in a pharmacy reference book (Martindale 2005) allowed us to identify European countries where Rheomacrodex® was still available: on 17 October 2005 a drug import company (Idis, London, UK) gave us a quotation for the importation of Rheomacrodex® from the Swedish manufacturer, Meda, but demanded an authorisation from AFSSaPS.
We called AFSSaPS on 18 October 2005 for practical instructions about the formalities. We were told by the Drug and Biological Products Evaluation Department that a parallel import authorisation (PIA) could only be granted to a pharmaceutical company, but not to a hospital pharmacy, but that a request for an import authorisation was possible.
Thus, we established an import authorisation dossier including the request form with mention of the planned use (clinically labelled use of a drug with a valid French MA) and a clinical argument.
The dossier was sent to AFSSaPS on 24 October 2005. On 5 December 2005, we were notified by phone that our request could not be examined because the French MA of Rheomacrodex® had been cancelled on 27 October 2005.
Discussion
Based on this case, comments can be made on juridical and organisational points.
First, as nowadays the European market is supposed to be "single" even for the personal use of drugs (Mäkinen et al. 2002) , it seems paradoxal that a hospital has to obtain an administrative authorisation to receive from another European Member State a drug regularly approved in both countries. This seems even in contradiction with the text of the regulations: the article R.5121-108 of FPHC refers only to drugs without MAs and states that the import authorisation may be refused if the drug could represent a risk for the public heath, which was obviously not the case. In our specific situation, the attitude of the import company, confirmed by AFSSaPS, seems excessive.
Second, the PIA definition (a drug approved in another European Union Member State and of the same composition as a French approved drug) was perfectly corresponding to our request. However, the AFSSaPs official denied us this pathway, which was reserved, according to her, for pharmaceutical companies, although article R.5121-120 of FPHC does not mention this restriction.
Even though we disagreed with AFSSaPS' interpretation of the law on these two points, we did not bring this case to court.
Third, it seems to us especially illogical that AFSSaPS, when asked for an import authorisation for a drug that it had previously approved itself, could imagine evaluating the clinical relevance of the request, as far as if it has been stated on this point when the MA was issued: for us, AFSSaPS would only act for the customs clearance.
Last, the conditions (43-day delay, phone call) by which we received the answer from AFSSaPS to our import request seem unacceptable. We can even speculate if the time convergence between our import request and the MA cancellation was fortuitous.
Conclusion
It seems absolutely necessary to clarify the juridical status of the circulation of drugs inside the European Union to make it simpler and safer. Extensive application of regulations by national authorities would merit improvements. A truely unified drug regulation in Europe is still awaited.
